fda compounding glp-1 warning letters october 2025 September 8, 2025: launches an import alert listing safe manufacturers – Partnership for Safe Medicines Dr. Elizabeth Kazarian, MD |

Despite their exploding popularity, the current GLP-1 injections (semaglutide though is also orally available) face accessibility issues due to cost and adverse effects and thus the next big move for the space, an easy to - pop pill could be lucrative, for which clinical trials are already well underway

h1 { line-height: 1em

But beyond appetite, researchers are uncovering another fascinating effect: changes in smell and fragrance perception

We're not friends anymore

Key points from the announcement: First oral GLP-1 approved for chronic weight management Once-daily tablet (no injection) Approval based on results from the OASIS clinical program Demonstrated significant and sustained weight loss U.S

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide and costs to consumers will triple, from $350 a month to $1,000.